Tech Company Inital Public Offerings
Clearside Biomedical IPO
Clearside Biomedical was acquired by . Shares were listed on 6/2/2016.
Transaction Overview
Company Name
Announced On
6/2/2016
Transaction Type
IPO
Amount
$50,400,000
Proceeds Purpose
We currently estimate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $15.0 million to complete our ongoing Phase 3 clinical trial of CLS-1001 in uveitis patients; approximately $14.0 million to initiate and begin conducting our Phase 3 clinical program for CLS-1003 in RVO patients; approximately $6.0 million to prepare our IND for, and complete our planned Phase 1/2 clinical trial of, CLS-1002 in wet AMD patients; and the remainder to fund continued research and development of our earlier-stage programs, including drug discovery for potential new applications for our SCS microinjection technology, and for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
900 North Point Pkwy. 200
Alpharetta, GA 30005
USA
Alpharetta, GA 30005
USA
Phone
Website
Email Address
Overview
Clearside BioMedical (Nasdaq: CLSD) is an ophthalmic company specializing in the research, development and commercialization of therapeutic products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Lasezkay
Chief Financial Officer
Charlie Deignan
VP - Bus. Development
Rick McElheny
VP - Product Management
Rafael Andino
Browse more venture capital transactions:
Prev: 6/2/2016: Sales Bootcamp venture capital transaction
Next: 6/2/2016: Vendini venture capital transaction
Share this article
News on VC Transactions
We record all VC transactions involving tech companies. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs